The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBig Technologies Regulatory News (BIG)

Share Price Information for Big Technologies (BIG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 150.00
Bid: 140.50
Ask: 148.50
Change: 0.00 (0.00%)
Spread: 8.00 (5.694%)
Open: 150.00
High: 150.00
Low: 150.00
Prev. Close: 150.00
BIG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Statement

19 Jan 2024 07:04

RNS Number : 2821A
Big Technologies PLC
19 January 2024

19 January 2024

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the Company's obligations under Article 17 of MAR.

Big Technologies plc

("Big Technologies" or the "Company" and the "Group")

Trading Update

Big Technologies plc, the UK-based remote people monitoring technology company, issues the following trading update ahead of the announcement scheduled for 26 March 2024 of its full year results for the year ended 31 December 2023.

The Group has continued to perform in line with the board's expectations with revenue for the year ended 31 December 2023 expected to be approximately £55 million (2022: £50.2 million) and adjusted EBITDA to be approximately £33 million (2022: £30.5 million). These results are in line with current market expectations1.

Outlook for 2024

Revenue from our contract to provide electronic monitoring services to one of our larger customers, based in Colombia, is expected to end during the first half of 2024. This contract has been subject to short term renewals since September 2021. A number of recent new contract wins are expected to partially offset the potential revenue loss from Colombia.

During the second half of 2023, we have significantly expanded our business development efforts in the US market, the largest market in the world for electronic monitoring and substance detection. We expect this investment to accelerate sales growth in the medium term, but the additional costs are expected to reduce operating profit margins in the US in 2024 until new sales are realised.

As a result of these developments, we expect Group sales for 2024 to be at least at the level achieved in 2022. More detailed guidance for 2024 will be given at the time of our results in March when the outcome in Colombia is known with greater certainty.

The Group continues to see opportunities to expand market share and scale-up the business and is in the process of releasing its first innovative substance detection technology to priority customers. We have enjoyed contract renewals across the business and won a number of new customers in recent months which will start to contribute revenues during 2024 and 2025. A return to growth is expected for 2025 and beyond.

1: The Company has compiled forecasts from four analysts with current market forecasts for 2023 revenue to be in the range of £54.0 to £54.5m, with a consensus of £54.3m, and for adjusted EBITDA to be in the range of £32.7m to £32.8m, with a consensus of £32.7m.

Sara Murray OBE, Chief Executive Officer, commented:

"In difficult market conditions, 2023 has seen the Group deliver a strong performance with continued growth in sales, profits and our cash reserves. We continue to invest in the business and in our market-leading suite of monitoring products and expect to see growth in the coming years. We are obviously disappointed with the outcome in Colombia, with a customer that we have served well for a number of years. We see a pipeline of attractive business opportunities around the globe and will continue to work diligently to replace this revenue stream."

For further information please contact:

Big Technologies

+44 (0) 19 2360 1910

Sara Murray (Chief Executive Officer)

Daren Morris (Chief Financial Officer)

Zeus (Nominated Adviser and Sole Broker)

+44 (0) 20 3829 5000

Jamie Peel / Dan Bate / Kieran Russell (Investment Banking)

Benjamin Robertson (Equity Capital Markets)

About Big Technologies

Big Technologies is the parent company of Buddi, which was founded in 2005 by its current CEO, Sara Murray, following an initial idea to create a GPS device small enough for a child to carry. Today, Big Technologies is a proven supplier of innovative and high-quality products and services to the remote personal monitoring industry. Big Technologies provides products and services under a number of brand and trading names, with 'Buddi' being the most well-known and being used in respect of activities within the core criminal justice market. Big Technologies (under the buddi brand) has created a leading, integrated technology platform (including both hardware and software solutions) for remote monitoring of individuals, providing state-of-the-art Electronic Monitoring (EM) solutions on a SaaS-like, subscription basis.

Electronic Monitoring in the criminal justice sector involves utilising location technologies to remotely monitor and manage people at all stages of the criminal justice system. The Company's focus on the Criminal Justice market in the immediate term has been demand-driven, with significant opportunities created by a combination of favourable market tailwinds as electronic location devices are increasingly recognised as alternatives to imprisonment, and superior technological capability enabling the Company to meet this demand effectively.

Big Technologies' criminal justice solution has been iteratively developed over a 10-year period, utilising the knowledge of an experienced management team listening to customers. The solution consists of a proprietary software platform with modular monitoring hardware, capable of being adapted to multiple applications. The Company's criminal justice solution is principally focussed around the "Buddi Smart Tag", an electronic monitoring hardware device, and "Buddi Eagle", the in-house developed, cloud-based monitoring software. Collectively, the hardware and the intelligent tools integrated into Big Technologies' software enable real-time tracking of monitored individuals with high levels of accuracy and reliability. Buddi evidences a substantial reduction in false alerts when compared to competitor systems which, combined with the reduction in subsequent investigations, can result in substantial cost savings for customers.

In addition to the high levels of accuracy, the Buddi Smart Tag has several key advantages over its competitors' devices. The tag is lighter, smaller, has longer battery life and offers a simple, contact free and shorter installation process, providing substantial staff cost savings for customers. This superior product design, coupled with the intelligent monitoring software, typically comes at a small price premium to competitor devices. However, the overall effectiveness and reliability of the solution, combined with the substantial cost savings delivered as a result of reduced monitoring costs, have helped Big Technologies deliver strong revenue growth from both existing and new customers. The Company leases its devices and software solutions to customers typically based on daily or monthly rates.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
TSTGZGMMNLMGDZG
12
Date   Source Headline
26th Apr 202411:28 amRNS2023 Annual Report and Notice of AGM
26th Mar 20247:00 amRNS2023 Preliminary audited results
22nd Feb 202411:35 amRNSHolding(s) in Company
5th Feb 20244:25 pmRNSDirector/PDMR Shareholding
29th Jan 20247:05 amRNSResponse to press speculation
26th Jan 202411:07 amRNSDirector/PDMR Shareholding
23rd Jan 20247:00 amRNSDirector/PDMR Shareholding
23rd Jan 20247:00 amRNSEBT Share Purchase
23rd Jan 20247:00 amRNSDirector/PDMR Shareholding
22nd Jan 20242:23 pmRNSDirector/PDMR Shareholding
22nd Jan 202412:12 pmRNSHolding(s) in Company
19th Jan 20247:04 amRNSTrading Statement
22nd Dec 202311:30 amRNSHolding(s) in Company
21st Dec 20231:35 pmRNSEBT Share Purchase
20th Dec 20232:16 pmRNSDirector/PDMR Shareholding
8th Dec 20233:05 pmRNSDirector/PDMR Shareholding
8th Dec 20237:00 amRNSEBT Share Purchase
6th Dec 20232:06 pmRNSEBT Share Purchase
4th Dec 202312:40 pmRNSEBT Share Purchase
20th Nov 202310:58 amRNSEBT Share Purchase
10th Nov 20239:08 amRNSDirector/PDMR Shareholding
8th Nov 20231:48 pmRNSEBT Share Purchase
1st Nov 20231:42 pmRNSEBT Share Purchase
25th Oct 202310:22 amRNSDirector/PDMR Shareholding
24th Oct 20234:57 pmRNSDirector/PDMR Shareholding - Replacement
24th Oct 202312:23 pmRNSDirector/PDMR Shareholding
24th Oct 202311:55 amRNSDirector/PDMR Shareholding - Replacement
23rd Oct 20235:05 pmRNSDirector/PDMR Shareholding
23rd Oct 20235:03 pmRNSEBT Share Purchase
18th Oct 20237:00 amRNSDirector/PDMR Shareholding
16th Oct 20239:05 amRNSIncrease in Share Capital
11th Oct 20231:40 pmRNSEBT Share Purchase
10th Oct 202311:40 amRNSEBT Share Purchase
3rd Oct 20237:00 amRNSEBT Share Purchase
28th Sep 20237:00 amRNSEBT Share Purchase
21st Sep 20237:00 amRNSEstablishment of an Employee Benefit Trust
19th Sep 20237:00 amRNSHalf-year Report
4th Aug 20238:57 amRNSStatement re legal claim
18th Jul 20237:00 amRNSIncrease in share capital and director dealing
7th Jun 20237:00 amRNSIncrease in share capital
23rd May 20231:43 pmRNSResult of AGM
23rd May 20237:00 amRNSAGM Statement
17th May 20232:10 pmRNSIncrease in Share Capital
26th Apr 20231:40 pmRNS2022 Annual Report and Notice of AGM
21st Apr 202310:27 amRNSDirector/PDMR Shareholding
5th Apr 20231:04 pmRNSDirector/PDMR Shareholding
4th Apr 202312:27 pmRNSDirector/PDMR Shareholding
31st Mar 202312:12 pmRNSIncrease in Share Capital
29th Mar 20237:00 amRNS2022 Preliminary audited results
23rd Mar 20231:01 pmRNSHolding(s) in Company
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.